Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, et al
Dual GIP/GLP-1 agonists add GIP receptor activation, which: Amplifies insulin secretion beyond what GLP-1 alone achieves Increases insulin sensitivity in peripheral tissues Appears to shift adipocyte metabolism toward fat oxidation (mechanism still under investigation) May reduce the nausea signal that limits GLP-1 dose escalation (GIP has anti-emetic properties in animal models) The weight loss ceiling for tirzepatide is approximately 20% to 22% of baseline body weight at the 15 mg dose over 72 weeks (SURMOUNT-1 data)
Quick Answer Weight loss plateaus on semaglutide are caused by metabolic adaptation, not medication failure
Maximizing Your Results with Lifestyle Support Medication is a powerful tool, but it works best when supported by a healthy foundation
A mass below 3,600 Da almost certainly means the fatty-acid conjugation was skipped